OXYGEN SENSING, HOMEOSTASIS, AND DISEASE SEMENZA. NEJM, AUGUST 2011, 246: 6 Amelia Crawford PA-S2.

Slides:



Advertisements
Similar presentations
Oxygen Therapy By Dr. Yasser Moustafa Assist. Prof.Pulmonology Ain Shams University.
Advertisements

 Cardiovascular System – Heart and Blood Vessels Topics in Human Pathophysiology Fall 2011 Gilead Drug Safety and Public Health.
Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.
A M.I.N.Y. MOUSE Production: Munasha, Ivan, Noor, Yuna Also featuring: Stephen M. and Julie R.
Care of Patients with Shock
Aging of the Cardiovascular System (continued)
Hallmarks of Cancer Six fundamental changes 1.Self sufficiency in growth factors 2.Insensitivity to growth-inhibitory signals 3.Evasion of apoptosis 4.Limitless.
CORONARY CIRCULATION DR. Eman El Eter.
Ischemic heart disease
What is Cancer? How it occurs and cell cycle regulation.
Heart control DR. HANA OMER.
Cancer: when our own cells become the enemy
Hypoxia Inducible Factor – 1 (HIF-1): A High Impact Factor Free Radical & Radiation Biology College of Medicine The University of Iowa
Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
CORONARY CIRCULATION DR. Eman El Eter. Coronary Arteries The major vessels of the coronary circulation are: 1- left main coronary that divides into left.
Inquiry into Life Twelfth Edition Chapter 25 Lecture PowerPoint to accompany Sylvia S. Mader Copyright © The McGraw-Hill Companies, Inc. Permission required.
Autoregulation The Renin-angiotensin-aldosterone (RAA) system is an important endocrine component of autoregulation. Renin is released by kidneys when.
BME- Short Presentation SHANTE DEZRICK 11/7/12. Common denominator in most common diseases. New capillary blood vessel growth in the body. Natural process.
Control of Gene Activity Chapter 17. Controlling gene activity Remember to control the cell one must control protein synthesis. Remember to control the.
Characteristics of Cancer. Promotion (reversible) Initiation (irreversible) malignant metastases More mutations Progression (irreversible)
Frank-Starling Mechanism
Respiratory failure Respiratory failure is a pathological process in which the external respiratory dysfunction leads to an abnormal decrease of arterial.
Essentials of Biology Sylvia S. Mader
5 – hydroxytryptamine and purines Serotonin was the name given to unknown vasoconstrictor substance found in the serum after blood has clotted. It was.
Notes - Cancer and Cell Division
Human Transport System
Ischemic Heart Disease Dr. Ravi Kant Assistant Professor Department of General Medicine.
Gene Therapy Prof. Dr. Marlina, MS, Apt Kuliah I 14 Maret 2011 Mata Kuliah: Bioteknologi Farmasi.
Differentiate Pulmonary arterial hypertension from pulmonary venous congestion.
 Heart disease remains the leading cause of morbidity and mortality in industrialized nations.  40% of all deaths in the U.S.A (nearly twice the number.
Regulation of Potassium K+
Diseases and Disorders of the Cardiovascular System.
Gene Therapy. What is Gene Therapy? Gene Therapy is the insertion of genes into an individual’s cells and tissues to treat a disease. Gene Therapy is.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Relationship Between Vascular Endothelial Growth.
TUMOR ANGIOGENESIS. Formation of new blood vessels is called angiogenesis Tumor angiogenesis is the proliferation of a network of blood vessels that penetrates.
Targeting of reactive oxygen species can be a potential therapeutic strategy for cancer treatment Ying-Ray Lee 1, San-Yuan Chen 2, and Hau-Ren Chen 3 1.
EUKARYOTIC CELL SIGNALING VII Abnormal Signaling in Cancer Signaling to p53 Dr. Ke Shuai Office: 9-240M Factor Tel: X69168
The Problem of Cancer. What are cancer cells ? Cancerous growth involves unrestrained proliferation (malignancy) and spread (metastasis). Caused by: mutations.
Human Physiology Respiratory System
VASOACTIVE DRUGS February 2017
Regulation of the Cell Cycle
Von Hippel-Lindau Syndrome
Ischemic Heart Disease
Daratumumab Drugbank ID : DB09043.
Arne R. M. van der Bilt, Elisabeth G. E
Angiogenesis and hepatocellular carcinoma
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
Silencing of eIF3e promotes blood perfusion recovery after limb ischemia through stabilization of hypoxia-inducible factor 2α activity  Takuya Hashimoto,
Hypoxia-Inducible Factors Link Iron Homeostasis and Erythropoiesis
Esther Bridges, Adrian L. Harris  Cancer Cell 
Volume 26, Issue 5, Pages (November 2014)
ROS Function in Redox Signaling and Oxidative Stress
Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34- positive endothelial cells in a hindlimb ischemia model: Implications for.
Drugs Acting on the Renin-Angiotensin-Aldosterone System
Angiogenesis and hepatocellular carcinoma
Environmental Carcinogenesis
Volume 26, Issue 5, Pages (November 2014)
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Volume 21, Issue 4, Pages (April 2013)
ID Proteins Regulate Diverse Aspects of Cancer Progression and Provide Novel Therapeutic Opportunities  Radhika Nair, Wee Siang Teo, Vivek Mittal, Alexander.
Hypoxia-Inducible Factors in Physiology and Medicine
Into Thin Air: How We Sense and Respond to Hypoxia
Process and mechanisms of blood vessel formation.
Passing the baton: the HIF switch
Endothelial Cells Form a Phalanx to Block Tumor Metastasis
Intratumoral hypoxia, radiation resistance, and HIF-1
Adrenergic Antagonist
Post-ischemic vascular repair mechanisms and the growth factors involved. Post-ischemic vascular repair mechanisms and the growth factors involved. The.
Ping-Pui Wong, Natalia Bodrug, Kairbaan M. Hodivala-Dilke 
Presentation transcript:

OXYGEN SENSING, HOMEOSTASIS, AND DISEASE SEMENZA. NEJM, AUGUST 2011, 246: 6 Amelia Crawford PA-S2

Hypoxia Inducible Factor 1  All nucleated cells in the human body respond to hypoxia  HIF-1 plays a critical role in the cells’ response.  When oxygen availability is decreased, HIF-1 regulates the expression of genes that mediate adaptive responses by cells

Hypoxia Inducible Factor 1  HIF-1 is composed of a beta and an alpha subunit.  The alpha subunit is oxygen regulated  In aerobic conditions, HLF-1 (alpha) is normally hydroxylated and then degraded by proteasomes  In hypoxic conditions, the hydroxylation is inhibited, HIF-1 (alpha) accumulates, and it up regulates several genes to promote survival in cells  Stimulates erythropoetin, angiogenesis, & glycolytic metabolism

HIF-1

HIF-1 and Cardiovascular Disease  Atherosclerotic disease causes stenosis of vessels and results in decreased blood flow distally.  Decreased blood flow → decreased O2 supply  In studies with mice in which the femoral artery was ligated, induction of HIF-1 resulted in increased activation of VEGF, which eventually caused angiogenesis and reperfusion of the limb via the production of collateral blood flow.  The normal adaptive vascular response is impaired by aging & DM—major causes of CAD and PVD

HIF-1 and Cardiovascular Disease  VEGF other factors promote angiogenesis by stimulating vascular cells and also by mobilizing bone-marrow derived angiogenic cells (BMDACs)  BMDACs = myeloid cells that stimulate vascular remodeling.  In order to initiate a vascular response, they must mobilized from bone marrow, enter the peripheral blood, and be retained within the ischemic tissue by adhering to the vascular endothelium.  Aging results in the loss of ischemia induced expression of angiogenic factors and BMDAC mobilization and consequently, angiogenesis and reperfusion are decreased.

HIF-1 and Cardiovascular Disease  HIF-1 α induction occurs early in the course of a MI  In studies with mice with an over expression of HIF-1 α that underwent coronary artery ligation, there was a smaller infarct size, improved cardiac function, and increased capillary density.  Collateral vessels are routinely identified in 2/3 of patients with critical coronary artery disease that is sufficient to cause angina.  Patients with a collateral blood supply that eventually suffered a MI also had smaller infarcts and were more likely to survive than those without a collateral vessels.  HIF-1 also helps the heart to survive episodes of O2 deprivation by inducing glycolytic metabolism & adenosine production

HIF-1 and Cardiovascular Disease  Pharmacologic agents that activate HIF-1 are a therapeutic target in treating patients with CAD and PVD (Gene therapy)  In preclinical trials, patients with CAD or PVD were given a recombinant adenovirus that encoded for a protein that contained the terminal half of HIF-1 alpha gene fused to an activator protein.  It was administered either via an IM injection (PVD) or intramyocardial injections (CAD) prior to CABG  No adverse effects were seen but also no reports of efficacy were released. This could be due to the fact that the protein did not contain all of the HIF-1 alpha gene and in turn did not encode for all the activities of the gene.

HIF-1 and Cardiovascular Disease  Another pharmacologic alternative for targeting HIF-1 in cardiovascular disease is the development of drugs that inhibit the hydroxylation of HIF-1.  These drugs either:  1. chelate Fe, (Fe is present in the center of the hydroxylases) or  2. compete with the hydroxylases at the binding site

HIF-1 and Cardiovascular Disease  A final alternative would be the use of HIF target gene products as therapeutic agents.  Already been done via cloning of erythropoietin gene and production of recombinant human erythropoietin.  Used in chronic renal failure patients to stimulate RBC production  However administration of a single angiogenic factor such as VEGF fails to stimulate a vascular response.  Benefit of using downstream proteins as therapeutic agents is that they act immediately whereas gene therapy requires more time for trascription and translation of target gene products.

HIF-1 and Cancer  In cancer the physiologic responses to hypoxia aids in disease progression  Tumor vessels are structurally & functionally abnormal and contain areas of severe hypoxia.  This results in HIF-1 over expression, which causes additional angiogenesis, genetic instability, immune evasion, metabolic reprogramming, and invasion, and metastasis.

HIF-1 and Cancer  Hypoxia within the tumor is a major mechanism that activates HIF-1  Loss of tumor suppressor function or increased oncogene function also activates HIF-1.  HIF-1 regulates a myriad of target genes  However, only a small subset of genes in any given cancer will be regulated by HIF-1  The role of HIF-1 in a specific cancer can guide possible therapies.

HIF-1 and Cancer  A number of chemotherapy agents are directed at inhibiting HIF-1  Topotecan  Also cardiac glycosides like Digoxin have been shown to decrease HIF-1 and subsequent tumor growth in mice.  Others are agents aimed at blocking HIF-1 are being investigated

HIF-1 and Pulmonary Hypertension  Pulmonary hypertension is a progressive and often fatal consequence of chronic lung disease  In contrast to systemic arterioles which dilate in order to increase tissue perfusion during hypoxia, pulmonary arterioles constrict to shunt blood away from areas of the lung that are not ventilated  This eventually leads to cor pulmonale and progressive hypoxemia.

HIF-1 and Pulmonary Hypertension  HIFs regulate target genes that play major roles in the pathology of pulmonary HTN.  Alveolar hypoxia induces HIF-1 activity in vascular smooth muscle cells and alters the intracellular concentrations of K, Ca, & H ions  This leads to smooth muscle cell hypertrophy, proliferation, depolarization, & contraction and increased pulmonary vascular resistance

HIF-1 and Pulmonary Hypertension  Tibetans live in conditions of chronic hypoxia & they have blunted responses to hypoxia, which prevents the development of pulmonary hypertension.  Gene sequencing has revealed loci encoding HIF-2 α, hyroxylases (PHD2), factor inhibiting HIF-1, and HIF target genes as playing a significant role in the adaptation that Tibetans exhibit.  Alters vascular, erythropoeitic, and metabolic responses to hypoxia

Conclusions  HIF-1 is an adaptive response in cardiovascular and peripheral vascular disease  HIF-1 is mal-adaptive in cancer  HIF-1 is also maladaptive in chronic lung disease and pulmonary hypertension.  The targeting of HIFs and its inhibitors and activators offer possible treatment options of these diseases.